Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Orladeyo?

See the DrugPatentWatch profile for Orladeyo

Orladeyo is a medication used to treat hereditary angioedema (HAE) [1]. It is taken orally once daily [1].

What is Hereditary Angioedema (HAE)?


Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling [1]. These attacks can affect the limbs, abdomen, face, and airway [1].

How Does Orladeyo Work?


Orladeyo's active ingredient is Berotralstat [1]. It is a plasma kallikrein inhibitor [1]. By inhibiting plasma kallikrein, it helps to prevent the swelling attacks associated with HAE [1].

When Can Orladeyo Be Used?


Orladeyo is approved for the prophylactic treatment of HAE in patients 12 years of age and older [1]. Prophylactic treatment means it is used to prevent attacks, rather than to treat an attack that is already happening [1].

What are the Potential Side Effects of Orladeyo?


Common side effects reported in clinical trials include gastrointestinal issues such as diarrhea, abdominal pain, and nausea [1]. Some patients may also experience upper respiratory tract infections, headache, or rash [1].

How is Orladeyo's Patent Status?


Information on Orladeyo's patent status, including expiry dates and any challenges, can be found on specialized patent tracking websites [2]. DrugPatentWatch.com is a resource that provides detailed data on drug patents and exclusivity [2].

What Other Treatments Are Available for HAE?


Besides Orladeyo, other HAE treatments include intravenous and subcutaneous self-administered therapies, as well as on-demand medications to treat acute attacks [1]. These can include C1 esterase inhibitor concentrates, kallikrein inhibitors, and bradykinin B2 receptor antagonists [1].

How Does Orladeyo Compare to Other HAE Treatments?


Orladeyo offers an oral, once-daily prophylactic option for HAE management [1]. This contrasts with some other long-term prophylactic treatments that require injections [1]. However, its efficacy and safety profile are distinct from other available therapies [1].

Sources:
[1] https://www.orladeyo.com/
[2] https://drugpatentwatch.com/



Other Questions About Orladeyo :

Orladeyo berotralstat synthesis patent? Biocryst pharmaceuticals orladeyo patent lawsuit? Orladeyo approval date? Orladeyo berotralstat synthesis patent? Orladeyo berotralstat synthesis patent?